Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis.

Published
August 28, 2020
Journal
Thrombosis research
PICOID
373fb050
DOI
Citations
179
Keywords
Anticoagulants, COVID-19, Pulmonary embolism, SARS virus, Venous thromboembolism
Copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Patients/Population/Participants

patients with COVID-19

Intervention

evaluation of incidence of VTE

Comparison

standard algorithms for clinically suspected VTE vs. other diagnostic strategies or patient sampling

Outcome

incidence of VTE, including PE and/or DVT

Abstract

P
I
C
O

Venous thromboembolism (VTE) may complicate the course of Coronavirus Disease 2019 (COVID-19). To evaluate the incidence of VTE in patients with COVID-19. MEDLINE, EMBASE, and PubMed were searched up to 24th June 2020 for studies that evaluated the incidence of VTE, including pulmonary embolism (PE) and/or deep vein thrombosis (DVT), in patients with COVID-19. Pooled proportions with corresponding 95% confidence intervals (CI) and prediction intervals (PI) were calculated by random-effect meta-analysis. 3487 patients from 30 studies were included. Based on very low-quality evidence due to heterogeneity and risk of bias, the incidence of VTE was 26% (95% PI, 6%-66%). PE with or without DVT occurred in 12% of patients (95% PI, 2%-46%) and DVT alone in 14% (95% PI, 1%-75%). Studies using standard algorithms for clinically suspected VTE reported PE in 13% of patients (95% PI, 2%-57%) and DVT in 6% (95% PI, 0%-60%), compared to 11% (95% PI, 2%-46%) and 24% (95% PI, 2%-85%) in studies using other diagnostic strategies or patient sampling. In patients admitted to intensive care units, VTE occurred in 24% (95% PI, 5%-66%), PE in 19% (95% PI, 6%-47%), and DVT alone in 7% (95% PI, 0%-69%). Corresponding values in general wards were respectively 9% (95% PI, 0%-94%), 4% (95% PI, 0%-100%), and 7% (95% CI, 1%-49%). VTE represents a frequent complication in hospitalized COVID-19 patients and often occurs as PE. The threshold for clinical suspicion should be low to trigger prompt diagnostic testing.

Similar article map

CEO: Hwi-yeol YunCOO: Jung-woo ChaeCTO: Sangkeun Jung
Location: 204, W6, Chungnam National University, 99, Daehak-ro, Yuseong-gu, Daejeon, Republic of Korea
Tel: 042-821-7328E-mail: webmaster@lilac-co.kr
Copyright © 2024 by LiLac. All Rights Reserved.